Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New insights into the management of renal cell cancer.
Pécuchet N, Fournier LS, Oudard S. Pécuchet N, et al. Among authors: oudard s. Oncology. 2013;84(1):22-31. doi: 10.1159/000342962. Epub 2012 Oct 16. Oncology. 2013. PMID: 23076127 Review.
Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M, Rolland F, Fumoleau P, Bugat R, Houyau P, Monnier A, Sun X, Montcuquet P, Breza J, Novak J, Gil T, Chopin D. Oudard S, et al. Ann Oncol. 2001 Jun;12(6):847-52. doi: 10.1023/a:1011141611560. Ann Oncol. 2001. PMID: 11484963 Free article. Clinical Trial.
Prognostic factors of renal cell carcinoma.
Méjean A, Oudard S, Thiounn N. Méjean A, et al. Among authors: oudard s. J Urol. 2003 Mar;169(3):821-7. doi: 10.1097/01.ju.0000051378.14270.2a. J Urol. 2003. PMID: 12576793 Review.
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM, et al. Among authors: oudard s. J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073. J Clin Oncol. 2003. PMID: 14581421 Clinical Trial.
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Oudard S, et al. J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738542 Clinical Trial.
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S; GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Oudard S, et al. J Urol. 2007 May;177(5):1698-702. doi: 10.1016/j.juro.2007.01.063. J Urol. 2007. PMID: 17437788 Clinical Trial.
431 results